Modular Medical, Inc. · NASDAQ:MODD
Modular Medical — Investor Presentation (September 2026)
19 slides from Modular Medical's investor presentation, September 2026
Slide 1: Investor Presentation
Investor Presentation NASDAQ:MODD September 2026
Slide 2: Forward Looking Statements, Other Disclaimers
2| Forward Looking Statements, Other Disclaimers. This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Secur
Slide 3: Corporate Overview
3| Corporate Overview Modular Medical is commercializing a next generation insulin pump designed to expand access to a higher standard of glycemic management for people with diabetes . Founded by Paul DiPerna, founder of Tandem Diabetes (TNDM) and original designer of its popular t:slim pump and 30-
Slide 4: Insulin Pumps Current Market
4| Insulin Pumps Current Market Represent the gold standard in glycemic • 1 in 4 Healthcare dollars in the US are spent on diabetes control. Better outcomes, better patient and diabetes related complications. 3 health, lower A1C. (Market share leaders: Medtronic, Tandem, Insulet) • Only 1 in 3 Ameri
Slide 5: US Market Size
5| US Market Size 27 million people with diabetes. 4.88 million require daily insulin (2M Type 1, 2.88M Type 2). Pumps CGM MDI Only 20% of insulin dependent people with diabetes use a pump for insulin delivery. 3,704,795 3,038,160 80% rely on multiple daily injections (MDI). Continuous glucose monit
Slide 6: Encouraging Adoption
6| Encouraging Adoption FreeStyle Libre vs. Dexcom Revenue Abbott Freestyle Libre made continuous glucose monitoring easier and more affordable. This expanded 800 the product category and doubled its size. 700 We believe the insulin pump 600 market is ready for a similar Revenue (Millions of USD) 50
Slide 7: Potential $3B US Market of Almost Pumpers
7| Potential $3B US Market of Almost Pumpers HCPs fairly consistently indicated that about 25% of their MDI population are “almost pumpers”, meaning that they have considered going on a pump, understand pump therapy benefits, but want something simpler that doesn’t have all the "bells and whistles”.
Slide 8: Pivot Insulin Delivery for Almost Pumpers
8| Pivot Insulin Delivery for Almost Pumpers Push button to bolus • Eliminate trade offs to expand the market. 90-day reusable pump • Same accuracy as leading pumps. No external controller • Patch pump with full sized 3-day required 3ml reservoir. cartridge No charging or battery replacement • Lates
Slide 9: MODD1 Technology Platform Designed to Provide Precision and Safety
9| MODD1 Technology Platform Designed to Provide Precision and Safety • Precision micro-dosing limits excessive insulin exposure and preserves insulin molecule integrity • More continuous insulin delivery with small increments as needed, not locked into five-minute intervals like other pumps • 8 fam
Slide 10: Simple Design Enables Automated, High-Volume Manufacturing
10 | Simple Design Enables Automated, High- Volume Manufacturing Insulet Pivot Omnipod
Slide 11: Pivot Shipped to Initial Customers, Launching in Five Key U.S. Markets by October 2026
11 | Pivot Shipped to Initial Customers, Launching in Five Key U.S. Markets by October 2026 5 Markets Target High-Volume Endocrinologists 14% 15% 21% of the nation’s highest-volume insulin of prescribers with high affinity for new pump prescribers of all new insulin pump starts brand adoption in MDI
Slide 12: Underserved Insulin Prescribers
12 | Underserved Insulin Prescribers 25% 75% US Patients With Diabetes Seen by Primary Care Physicians US Patients With Diabetes Seen by Endocrinologists Primary care physicians are uncomfortable prescribing 4,000 Endocrinologists Serve These Patients 2 current pumps. Patients utilizing multiple dai
Slide 13: Positioning for Full-Scale Commercialization in 2027
Positioning for Full-Scale Commercialization in 13 | 2027 • Gathering Pivot customer and doctor feedback across initial 5 markets. • Partnered with Inizio for provider engagement and commercialization execution. • Established Pivot Innovation Council chaired by Dr. Gabbay to guide commercialization
Slide 14: The Team
14 | The Team Paul DiPerna James (Jeb) Kevin Schmid President, CFO & Chairman Besser Chief Operating Officer Chief Executive Officer 30 years of experience in medical device industry • Led over 10 projects to FDA • 23 year Managing Member, • 19+ years in medical device approval Manchester Management
Slide 15: Capital Structure
15 | Capital Structure Stock Information (at August 24, 2026) Listing NASDAQ Symbol MODD Price Per Share $3.74 Market Cap $30.5M Share Structure Shares Outstanding (8/14/26) 8.15 M Executive & Insider Ownership 4.9% Warrants Outstanding (6/30/26) 3.2 M Wtd. Avg. Warrant Exercise Price $20.33 Options
Slide 16: Investor Relations
16 | Investor Relations ir@modular-medical.com NASDAQ:MO DD
Slide 17: Appendix
17 | Appendix.
Slide 18: 2024 Pump Market Share
18 | 2024 Pump Market Share PRODUCT INSTALLED BASE MARKET SHARE Medtronic 291,000 32% Insulet 246,000 28% Tandem 320,000 36% Other 33,000 4% Seagrove Partners LLC, August 2024 Bluebook
Slide 19: How does a doctor put a patient on a pump?
19 | How does a doctor put a patient on a pump? *Increasing Equitable Access in Diabetes Tech among Patients with Type 1 Diabetes Across a Health System, Suma Gondi, MD et a l.
Modular Medical — Investor Presentation (September 2026) on 6ix